Multiple Myeloma Guideline Update 2025

Shaji Kumar, MD, discusses how the FDA approval of linvoseltamab, a new BCMA-targeted bispecific antibody for relapsed multiple myeloma, expands treatment options with its unique intravenous administration and flexible dosing schedule, while exploring its clinical outcomes, management strategies, and potential for earlier intervention in the disease course.